Scientific Advisory Board

Thought leaders in cancer immunotherapy, immunology, and gynecological oncology.

Darron R. Brown, M.D.

Click here for more information about Darron R. Brown, M.D.

Dr. Brown is a world-renowned immunologist and expert in the field of infectious diseases. Dr. Brown is currently a Professor of Medicine at the Indiana University School of Medicine, Indianapolis, IN. Dr. Brown is also a Professor of Microbiology and Immunology at the Indiana University School of Medicine. In addition to these duties, Dr. Brown is an attending physician at the Veterans Administration Medical Center and Infectious Diseases Outpatient Clinic, Indianapolis, IN, and also at the Indiana University Medical Center. Dr. Brown is widely regarded as an expert in the field of Human Papillomavirus (HPV) infection and has received several awards and fellowships from the National Institutes of Health, American Cancer Society and the pharmaceutical industry to study various aspects of HPV infection and disease. Dr. Brown has several leading publications in the field of HPV disease and is leading researcher in the field.  He has been a clinical consultant to several companies including Merck during the development of Gardasil®.

Robert P. Edwards, M.D.

Click here for more information about Robert P. Edwards, M.D.

Dr. Edwards is a leading and internationally recognized clinical oncologist and researcher in the field of gynecological oncology. Dr. Edwards is a tenured Professor and Vice Chairman of Clinical affairs of the Department of Obstetrics, Gynecology and Reproductive Sciences, at the University of Pittsburgh, School of Medicine. Dr. Edwards is also Director of Transformational Medicine at the University of Pittsburgh Medical Center. He is the executive vice chair of Gynecologic Services & Co-Director, Ovarian Cancer Center of Excellence at the Magee-Womens Hospital in Pittsburgh, where he is also the Director of Gynecologic Oncology Outreach and Research. Dr. Edwards’ research interests include immunotherapy and treatment of cervical and ovarian malignancies. He serves as principle investigator of the Gynecologic Oncology Group for the University of Pittsburgh and for a number of pharmaceutical-sponsored studies. Dr. Edwards has published widely in the field of gynecological oncology.

Mark Einstein, M.D.

Click here for more information about Mark Einstein, M.D.

Dr. Einstein is one of the world’s leading experts in gynecological and HPV disease including cervical and cancer. Mark H. Einstein, MD, is Professor and Chair of Obstetrics, Gynecology and Women’s Health at Rutgers New Jersey Medical School. Dr. Einstein is a Gynecologic Oncologist who is an expert at identification and treatment of gynecologic malignancies. His primary research interests focus on the pathogenesis, therapy, and prevention of lower anogenital tract and gynecologic cancers. He leads numerous clinical studies to identify unique targets and biomarkers for clinical risk of malignant transformation. He is also testing many novel drugs for cancer treatment. He has been an active leader for management guidelines and translating clinical trial and translational data for such organizations as the World Health Organization (WHO), American Cancer Society (ACS), Society of Gynecologic Oncology (SGO), American College of Obstetrics and Gynecology (ACOG), and Society of Lower Genital Tract Disease (ASCCP). He serves on the Boards for SGO and the ASCCP. He has served on numerous committees and leadership for the National Cancer Institute (NCI)-funded NRG Oncology group and AIDS Malignancy Consortium (AMC). Currently, he serves as a principal investigator on many multi-institutional clinical trials for gynecologic cancers in the US and Internationally. He has been funded for his research efforts by a number of organizations including the NCI, ACS, Foundation for Women’s Cancers, and others. Dr. Einstein has published widely in the field of HPV-related cancer and oncology. Dr. Einstein is a leading surgeon, key opinion leader and clinical expert in HPV infection and cancer and has worked with the FDA in developing regulatory pathways for immunotherapies and in designing HPV clinical trials.

Neil Gross, M.D.

Click here for more information about Neil Gross, M.D.

Dr. Gross is a surgeon-scientist with a very active clinical practice solely devoted to treating head and neck cancer patients. He currently serves as the Director of Clinical Research in the Department of Head and Neck Surgery at MD Anderson Cancer Center, with a focus on surgery-related clinical trials. He has a strong clinical and research interest in squamous cell carcinoma of the head and neck (SCCHN) including oropharynx cancer. He has managed a range of observational and therapeutic clinical trials for patients with head and neck cancer. Dr. Gross’s research efforts continue to focus on the epidemiology of human papillomavirus (HPV)-associated cancers of the head and neck, development and validation of improved prognostic tools for head and neck cancer patients, the study of the molecular basis of carcinogenesis in humans and the application of novel molecular therapeutics in cutaneous SCCHN and transoral robotic surgery (TORS).

Leaf Huang, Ph.D.

Click here for more information about Leaf Huang, Ph.D.

Dr. Huang is the Fred N. Eshelman Distinguished Professor and Chair, Division of Molecular Pharmaceutics, University of North Carolina, Chapel Hill. He is a renowned expert in the field of drug delivery and is the inventor of PDS Biotechnology Corporation’s Versamune™ technology and a cofounder of the company. Dr. Huang’s research has been in the areas of gene therapy and drug delivery. He produced the first ever liposome gene-delivery clinical trial in 1992. In 2004, he received the Alec D. Bangham Achievement Award, the highest honor in liposome drug delivery. He co-founded LipoGen and Rgene. Both companies were sold successfully. Dr. Huang holds a B.S. in physics and a Ph.D. in biophysics from Michigan State University.

Samir N. Khleif, M.D.

Click here for more information about Samir N. Khleif, M.D.

Dr. Khleif is a world renowned oncologist and Professor of Medicine, Medical College of Georgia. He is also Director of the Georgia Regents University Cancer Center. Dr. Khleif was formerly a Senior Investigator and Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and also served as a Special Assistant to the Commissioner of the Food and Drug Administration (FDA) leading the Critical Path Initiative for oncology. Dr. Khleif serves on many local, national, and international committees and as a cancer vaccine expert for a number of national organizations. From 2002 to 2006 Dr. Khleif served as the Director General and CEO of the King Hussein Cancer Center as part of an agreement between the NCI and Jordan. During that period Dr. Khleif lead the development of the only cancer center in the Middle East into an internationally recognized comprehensive cancer center of excellence. In 2007, Dr. Khleif was appointed, as part of a new agreement between the Health and Human Services Department/NCI and Jordan to develop the new Institute into a comprehensive cancer center and Biotechnology research hub for the Middle East. Dr. Khleif’s research interest is in identifying new and improved strategies to enhance specific immune response against cancer for preventive and therapeutic intent. His research group designed and performed some of the first cancer vaccine clinical trials targeting specific genetic changes in cancer cells.

Lisa Rohan, Ph.D.

Click here for more information about Lisa Rohan, Ph.D.

B.S., Chemical Engineering, Ph.D., Pharmaceutics — University of Pittsburgh

Dr. Rohan is Professor of Pharmaceutical Sciences in the School of Pharmacy and the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh School of Medicine. Additionally, she is an Investigator at the Magee Women’s Research Institute where among her other duties she holds a position on the Biotechnology Advisory Board for the Institute.  Dr. Rohan spent several years in the pharmaceutical industry.  She worked at major Pharmaceutical companies such as Sterling Drug, Kodak Pharmaceuticals, and Biodecision Laboratories.  At Biodecision Laboratories as Director of Client Services she was involved in clinical trial initiation, coordination, and protocol design.  She dealt frequently with the FDA in designing clinical studies.  She is a member of the Scientific Steering Committee of the Women’s Health Research Coalition.  She serves on various Special Emphasis Review Panels at the NIH.  Dr. Rohan’s research involves development of imaging techniques for sentinel node identification in cervical cancer as well as novel delivery systems for HIV prevention.

Jerold G. Woodward, Ph.D.

Click here for more information about Jerold G. Woodward, Ph.D.

Prof. Woodward is currently Professor, Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine. Prof. Woodward is an expert immunologist and has a wealth of experience working with nanoparticles and humanized transgenic mouse models. Ongoing projects in Prof. Woodward’s lab involve the role of different tissues in peripheral tolerance induction using the eye as a model system, the role of the antigen presenting cell in tolerance induction, the ability of tumor cells to escape immune recognition by inducing a state of tolerance and, the production of transgenic mice as models of autoimmune disease to study the role of tolerance in regulating autoimmunity. Prof. Woodward obtained his Ph.D. at the University of Utah and did postdoctoral studies at the University of Southern California.

  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway One
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144